nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—Hypersensitivity—Azathioprine—multiple sclerosis	0.00192	0.00207	CcSEcCtD
Dicyclomine—Malaise—Prednisolone—multiple sclerosis	0.00191	0.00206	CcSEcCtD
Dicyclomine—Nausea—Cladribine—multiple sclerosis	0.0019	0.00205	CcSEcCtD
Dicyclomine—Syncope—Prednisolone—multiple sclerosis	0.0019	0.00205	CcSEcCtD
Dicyclomine—Eye disorder—Betamethasone—multiple sclerosis	0.0019	0.00205	CcSEcCtD
Dicyclomine—Eye disorder—Dexamethasone—multiple sclerosis	0.0019	0.00205	CcSEcCtD
Dicyclomine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.00189	0.00204	CcSEcCtD
Dicyclomine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00188	0.00203	CcSEcCtD
Dicyclomine—Somnolence—Mitoxantrone—multiple sclerosis	0.00187	0.00202	CcSEcCtD
Dicyclomine—Loss of consciousness—Prednisolone—multiple sclerosis	0.00186	0.00201	CcSEcCtD
Dicyclomine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.00185	0.002	CcSEcCtD
Dicyclomine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00183	0.00198	CcSEcCtD
Dicyclomine—Hypertension—Prednisolone—multiple sclerosis	0.00183	0.00197	CcSEcCtD
Dicyclomine—Fatigue—Mitoxantrone—multiple sclerosis	0.00182	0.00196	CcSEcCtD
Dicyclomine—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.00181	0.00195	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.0018	0.00195	CcSEcCtD
Dicyclomine—Pain—Mitoxantrone—multiple sclerosis	0.0018	0.00194	CcSEcCtD
Dicyclomine—Constipation—Mitoxantrone—multiple sclerosis	0.0018	0.00194	CcSEcCtD
Dicyclomine—Discomfort—Prednisolone—multiple sclerosis	0.00178	0.00192	CcSEcCtD
Dicyclomine—Angioedema—Triamcinolone—multiple sclerosis	0.00178	0.00192	CcSEcCtD
Dicyclomine—Angioedema—Methylprednisolone—multiple sclerosis	0.00177	0.00192	CcSEcCtD
Dicyclomine—Erythema—Dexamethasone—multiple sclerosis	0.00177	0.00191	CcSEcCtD
Dicyclomine—Erythema—Betamethasone—multiple sclerosis	0.00177	0.00191	CcSEcCtD
Dicyclomine—Hallucination—Prednisone—multiple sclerosis	0.00176	0.0019	CcSEcCtD
Dicyclomine—Malaise—Triamcinolone—multiple sclerosis	0.00176	0.0019	CcSEcCtD
Dicyclomine—Malaise—Methylprednisolone—multiple sclerosis	0.00175	0.00189	CcSEcCtD
Dicyclomine—Syncope—Triamcinolone—multiple sclerosis	0.00175	0.00188	CcSEcCtD
Dicyclomine—Syncope—Methylprednisolone—multiple sclerosis	0.00174	0.00188	CcSEcCtD
Dicyclomine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00174	0.00187	CcSEcCtD
Dicyclomine—Oedema—Prednisolone—multiple sclerosis	0.00173	0.00187	CcSEcCtD
Dicyclomine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.00173	0.00187	CcSEcCtD
Dicyclomine—Dizziness—Azathioprine—multiple sclerosis	0.00172	0.00186	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00172	0.00186	CcSEcCtD
Dicyclomine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.00171	0.00185	CcSEcCtD
Dicyclomine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.00171	0.00184	CcSEcCtD
Dicyclomine—Shock—Prednisolone—multiple sclerosis	0.0017	0.00183	CcSEcCtD
Dicyclomine—Erectile dysfunction—Methotrexate—multiple sclerosis	0.0017	0.00183	CcSEcCtD
Dicyclomine—Tachycardia—Prednisolone—multiple sclerosis	0.00169	0.00182	CcSEcCtD
Dicyclomine—Hypertension—Triamcinolone—multiple sclerosis	0.00168	0.00181	CcSEcCtD
Dicyclomine—Hypertension—Methylprednisolone—multiple sclerosis	0.00168	0.00181	CcSEcCtD
Dicyclomine—Urticaria—Mitoxantrone—multiple sclerosis	0.00167	0.00181	CcSEcCtD
Dicyclomine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00166	0.0018	CcSEcCtD
Dicyclomine—Vomiting—Azathioprine—multiple sclerosis	0.00166	0.00179	CcSEcCtD
Dicyclomine—Eye disorder—Prednisone—multiple sclerosis	0.00165	0.00178	CcSEcCtD
Dicyclomine—Drowsiness—Methotrexate—multiple sclerosis	0.00165	0.00178	CcSEcCtD
Dicyclomine—Rash—Azathioprine—multiple sclerosis	0.00164	0.00177	CcSEcCtD
Dicyclomine—Dermatitis—Azathioprine—multiple sclerosis	0.00164	0.00177	CcSEcCtD
Dicyclomine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.00164	0.00177	CcSEcCtD
Dicyclomine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.00164	0.00177	CcSEcCtD
Dicyclomine—Discomfort—Triamcinolone—multiple sclerosis	0.00164	0.00177	CcSEcCtD
Dicyclomine—Discomfort—Methylprednisolone—multiple sclerosis	0.00163	0.00176	CcSEcCtD
Dicyclomine—Headache—Azathioprine—multiple sclerosis	0.00163	0.00176	CcSEcCtD
Dicyclomine—Dry mouth—Triamcinolone—multiple sclerosis	0.00162	0.00175	CcSEcCtD
Dicyclomine—Angioedema—Betamethasone—multiple sclerosis	0.00161	0.00174	CcSEcCtD
Dicyclomine—Angioedema—Dexamethasone—multiple sclerosis	0.00161	0.00174	CcSEcCtD
Dicyclomine—Confusional state—Methylprednisolone—multiple sclerosis	0.0016	0.00173	CcSEcCtD
Dicyclomine—Immune system disorder—Prednisone—multiple sclerosis	0.0016	0.00172	CcSEcCtD
Dicyclomine—Malaise—Dexamethasone—multiple sclerosis	0.00159	0.00172	CcSEcCtD
Dicyclomine—Malaise—Betamethasone—multiple sclerosis	0.00159	0.00172	CcSEcCtD
Dicyclomine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.00159	0.00172	CcSEcCtD
Dicyclomine—Oedema—Triamcinolone—multiple sclerosis	0.00159	0.00172	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.00159	0.00171	CcSEcCtD
Dicyclomine—Syncope—Betamethasone—multiple sclerosis	0.00158	0.00171	CcSEcCtD
Dicyclomine—Syncope—Dexamethasone—multiple sclerosis	0.00158	0.00171	CcSEcCtD
Dicyclomine—Shock—Triamcinolone—multiple sclerosis	0.00156	0.00169	CcSEcCtD
Dicyclomine—Insomnia—Prednisolone—multiple sclerosis	0.00156	0.00169	CcSEcCtD
Dicyclomine—Shock—Methylprednisolone—multiple sclerosis	0.00156	0.00168	CcSEcCtD
Dicyclomine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00155	0.00168	CcSEcCtD
Dicyclomine—Loss of consciousness—Betamethasone—multiple sclerosis	0.00155	0.00168	CcSEcCtD
Dicyclomine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00155	0.00168	CcSEcCtD
Dicyclomine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00155	0.00167	CcSEcCtD
Dicyclomine—Paraesthesia—Prednisolone—multiple sclerosis	0.00155	0.00167	CcSEcCtD
Dicyclomine—Tachycardia—Triamcinolone—multiple sclerosis	0.00155	0.00167	CcSEcCtD
Dicyclomine—Mental disorder—Prednisone—multiple sclerosis	0.00155	0.00167	CcSEcCtD
Dicyclomine—Nausea—Azathioprine—multiple sclerosis	0.00155	0.00167	CcSEcCtD
Dicyclomine—Tachycardia—Methylprednisolone—multiple sclerosis	0.00155	0.00167	CcSEcCtD
Dicyclomine—Erythema—Prednisone—multiple sclerosis	0.00154	0.00166	CcSEcCtD
Dicyclomine—Hypertension—Dexamethasone—multiple sclerosis	0.00153	0.00165	CcSEcCtD
Dicyclomine—Hypertension—Betamethasone—multiple sclerosis	0.00153	0.00165	CcSEcCtD
Dicyclomine—Asthenia—Mitoxantrone—multiple sclerosis	0.00151	0.00163	CcSEcCtD
Dicyclomine—Discomfort—Betamethasone—multiple sclerosis	0.00149	0.0016	CcSEcCtD
Dicyclomine—Discomfort—Dexamethasone—multiple sclerosis	0.00149	0.0016	CcSEcCtD
Dicyclomine—Pain—Prednisolone—multiple sclerosis	0.00148	0.00159	CcSEcCtD
Dicyclomine—Vision blurred—Prednisone—multiple sclerosis	0.00145	0.00156	CcSEcCtD
Dicyclomine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.00144	0.00156	CcSEcCtD
Dicyclomine—Oedema—Dexamethasone—multiple sclerosis	0.00144	0.00156	CcSEcCtD
Dicyclomine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.00144	0.00156	CcSEcCtD
Dicyclomine—Oedema—Betamethasone—multiple sclerosis	0.00144	0.00156	CcSEcCtD
Dicyclomine—Insomnia—Triamcinolone—multiple sclerosis	0.00144	0.00155	CcSEcCtD
Dicyclomine—Insomnia—Methylprednisolone—multiple sclerosis	0.00143	0.00155	CcSEcCtD
Dicyclomine—Ill-defined disorder—Prednisone—multiple sclerosis	0.00143	0.00154	CcSEcCtD
Dicyclomine—Paraesthesia—Triamcinolone—multiple sclerosis	0.00143	0.00154	CcSEcCtD
Dicyclomine—Feeling abnormal—Prednisolone—multiple sclerosis	0.00142	0.00154	CcSEcCtD
Dicyclomine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.00142	0.00154	CcSEcCtD
Dicyclomine—Shock—Dexamethasone—multiple sclerosis	0.00142	0.00153	CcSEcCtD
Dicyclomine—Shock—Betamethasone—multiple sclerosis	0.00142	0.00153	CcSEcCtD
Dicyclomine—Dyspnoea—Triamcinolone—multiple sclerosis	0.00142	0.00153	CcSEcCtD
Dicyclomine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00141	0.00153	CcSEcCtD
Dicyclomine—Nervous system disorder—Betamethasone—multiple sclerosis	0.00141	0.00153	CcSEcCtD
Dicyclomine—Agitation—Prednisone—multiple sclerosis	0.00141	0.00153	CcSEcCtD
Dicyclomine—Tachycardia—Dexamethasone—multiple sclerosis	0.00141	0.00152	CcSEcCtD
Dicyclomine—Tachycardia—Betamethasone—multiple sclerosis	0.00141	0.00152	CcSEcCtD
Dicyclomine—Angioedema—Prednisone—multiple sclerosis	0.00141	0.00152	CcSEcCtD
Dicyclomine—Dyspepsia—Triamcinolone—multiple sclerosis	0.0014	0.00151	CcSEcCtD
Dicyclomine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.0014	0.00151	CcSEcCtD
Dicyclomine—Malaise—Prednisone—multiple sclerosis	0.00139	0.0015	CcSEcCtD
Dicyclomine—Eye disorder—Methotrexate—multiple sclerosis	0.00138	0.00149	CcSEcCtD
Dicyclomine—Syncope—Prednisone—multiple sclerosis	0.00138	0.00149	CcSEcCtD
Dicyclomine—Anorexia—Dexamethasone—multiple sclerosis	0.00137	0.00148	CcSEcCtD
Dicyclomine—Anorexia—Betamethasone—multiple sclerosis	0.00137	0.00148	CcSEcCtD
Dicyclomine—Urticaria—Prednisolone—multiple sclerosis	0.00137	0.00148	CcSEcCtD
Dicyclomine—Cardiac disorder—Methotrexate—multiple sclerosis	0.00137	0.00148	CcSEcCtD
Dicyclomine—Fatigue—Triamcinolone—multiple sclerosis	0.00137	0.00148	CcSEcCtD
Dicyclomine—Fatigue—Methylprednisolone—multiple sclerosis	0.00137	0.00148	CcSEcCtD
Dicyclomine—Pain—Triamcinolone—multiple sclerosis	0.00136	0.00147	CcSEcCtD
Dicyclomine—Loss of consciousness—Prednisone—multiple sclerosis	0.00135	0.00146	CcSEcCtD
Dicyclomine—Vomiting—Mitoxantrone—multiple sclerosis	0.00134	0.00145	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—multiple sclerosis	0.00133	0.00144	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00133	0.00144	CcSEcCtD
Dicyclomine—Hypertension—Prednisone—multiple sclerosis	0.00133	0.00143	CcSEcCtD
Dicyclomine—Rash—Mitoxantrone—multiple sclerosis	0.00133	0.00143	CcSEcCtD
Dicyclomine—Dermatitis—Mitoxantrone—multiple sclerosis	0.00133	0.00143	CcSEcCtD
Dicyclomine—Headache—Mitoxantrone—multiple sclerosis	0.00132	0.00142	CcSEcCtD
Dicyclomine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00131	0.00141	CcSEcCtD
Dicyclomine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00131	0.00141	CcSEcCtD
Dicyclomine—Insomnia—Dexamethasone—multiple sclerosis	0.0013	0.00141	CcSEcCtD
Dicyclomine—Insomnia—Betamethasone—multiple sclerosis	0.0013	0.00141	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.0013	0.0014	CcSEcCtD
Dicyclomine—Paraesthesia—Dexamethasone—multiple sclerosis	0.00129	0.0014	CcSEcCtD
Dicyclomine—Paraesthesia—Betamethasone—multiple sclerosis	0.00129	0.0014	CcSEcCtD
Dicyclomine—Discomfort—Prednisone—multiple sclerosis	0.00129	0.0014	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—multiple sclerosis	0.00129	0.0014	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—multiple sclerosis	0.00129	0.00139	CcSEcCtD
Dicyclomine—Hypersensitivity—Prednisolone—multiple sclerosis	0.00127	0.00137	CcSEcCtD
Dicyclomine—Dyspepsia—Dexamethasone—multiple sclerosis	0.00127	0.00137	CcSEcCtD
Dicyclomine—Dyspepsia—Betamethasone—multiple sclerosis	0.00127	0.00137	CcSEcCtD
Dicyclomine—Urticaria—Triamcinolone—multiple sclerosis	0.00126	0.00136	CcSEcCtD
Dicyclomine—Urticaria—Methylprednisolone—multiple sclerosis	0.00126	0.00136	CcSEcCtD
Dicyclomine—Oedema—Prednisone—multiple sclerosis	0.00126	0.00136	CcSEcCtD
Dicyclomine—Anaphylactic shock—Prednisone—multiple sclerosis	0.00126	0.00136	CcSEcCtD
Dicyclomine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00125	0.00135	CcSEcCtD
Dicyclomine—Decreased appetite—Betamethasone—multiple sclerosis	0.00125	0.00135	CcSEcCtD
Dicyclomine—Decreased appetite—Dexamethasone—multiple sclerosis	0.00125	0.00135	CcSEcCtD
Dicyclomine—Nausea—Mitoxantrone—multiple sclerosis	0.00125	0.00135	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00124	0.00134	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00124	0.00134	CcSEcCtD
Dicyclomine—Fatigue—Betamethasone—multiple sclerosis	0.00124	0.00134	CcSEcCtD
Dicyclomine—Fatigue—Dexamethasone—multiple sclerosis	0.00124	0.00134	CcSEcCtD
Dicyclomine—Shock—Prednisone—multiple sclerosis	0.00124	0.00133	CcSEcCtD
Dicyclomine—Pain—Betamethasone—multiple sclerosis	0.00123	0.00133	CcSEcCtD
Dicyclomine—Pain—Dexamethasone—multiple sclerosis	0.00123	0.00133	CcSEcCtD
Dicyclomine—Nervous system disorder—Prednisone—multiple sclerosis	0.00123	0.00133	CcSEcCtD
Dicyclomine—Tachycardia—Prednisone—multiple sclerosis	0.00123	0.00132	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—multiple sclerosis	0.00121	0.00131	CcSEcCtD
Dicyclomine—Anorexia—Prednisone—multiple sclerosis	0.0012	0.00129	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.00119	0.00129	CcSEcCtD
Dicyclomine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00119	0.00128	CcSEcCtD
Dicyclomine—Feeling abnormal—Betamethasone—multiple sclerosis	0.00119	0.00128	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00118	0.00127	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00118	0.00127	CcSEcCtD
Dicyclomine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00117	0.00126	CcSEcCtD
Dicyclomine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00117	0.00126	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—multiple sclerosis	0.00116	0.00125	CcSEcCtD
Dicyclomine—Urticaria—Dexamethasone—multiple sclerosis	0.00115	0.00124	CcSEcCtD
Dicyclomine—Urticaria—Betamethasone—multiple sclerosis	0.00115	0.00124	CcSEcCtD
Dicyclomine—Dizziness—Prednisolone—multiple sclerosis	0.00114	0.00123	CcSEcCtD
Dicyclomine—Asthenia—Triamcinolone—multiple sclerosis	0.00114	0.00123	CcSEcCtD
Dicyclomine—Abdominal pain—Dexamethasone—multiple sclerosis	0.00114	0.00123	CcSEcCtD
Dicyclomine—Abdominal pain—Betamethasone—multiple sclerosis	0.00114	0.00123	CcSEcCtD
Dicyclomine—Asthenia—Methylprednisolone—multiple sclerosis	0.00114	0.00123	CcSEcCtD
Dicyclomine—Insomnia—Prednisone—multiple sclerosis	0.00114	0.00123	CcSEcCtD
Dicyclomine—Paraesthesia—Prednisone—multiple sclerosis	0.00113	0.00122	CcSEcCtD
Dicyclomine—Pruritus—Triamcinolone—multiple sclerosis	0.00112	0.00121	CcSEcCtD
Dicyclomine—Pruritus—Methylprednisolone—multiple sclerosis	0.00112	0.00121	CcSEcCtD
Dicyclomine—Dyspepsia—Prednisone—multiple sclerosis	0.00111	0.00119	CcSEcCtD
Dicyclomine—Decreased appetite—Prednisone—multiple sclerosis	0.00109	0.00118	CcSEcCtD
Dicyclomine—Rash—Prednisolone—multiple sclerosis	0.00109	0.00118	CcSEcCtD
Dicyclomine—Dermatitis—Prednisolone—multiple sclerosis	0.00109	0.00117	CcSEcCtD
Dicyclomine—Fatigue—Prednisone—multiple sclerosis	0.00108	0.00117	CcSEcCtD
Dicyclomine—Headache—Prednisolone—multiple sclerosis	0.00108	0.00117	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—multiple sclerosis	0.00108	0.00117	CcSEcCtD
Dicyclomine—Constipation—Prednisone—multiple sclerosis	0.00107	0.00116	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—multiple sclerosis	0.00106	0.00114	CcSEcCtD
Dicyclomine—Dizziness—Triamcinolone—multiple sclerosis	0.00105	0.00113	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.00105	0.00113	CcSEcCtD
Dicyclomine—Dizziness—Methylprednisolone—multiple sclerosis	0.00105	0.00113	CcSEcCtD
Dicyclomine—Feeling abnormal—Prednisone—multiple sclerosis	0.00103	0.00112	CcSEcCtD
Dicyclomine—Asthenia—Dexamethasone—multiple sclerosis	0.00103	0.00112	CcSEcCtD
Dicyclomine—Asthenia—Betamethasone—multiple sclerosis	0.00103	0.00112	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—multiple sclerosis	0.00103	0.00111	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00103	0.00111	CcSEcCtD
Dicyclomine—Nausea—Prednisolone—multiple sclerosis	0.00103	0.00111	CcSEcCtD
Dicyclomine—Pruritus—Dexamethasone—multiple sclerosis	0.00102	0.0011	CcSEcCtD
Dicyclomine—Pruritus—Betamethasone—multiple sclerosis	0.00102	0.0011	CcSEcCtD
Dicyclomine—Vomiting—Triamcinolone—multiple sclerosis	0.00101	0.00109	CcSEcCtD
Dicyclomine—Vomiting—Methylprednisolone—multiple sclerosis	0.00101	0.00109	CcSEcCtD
Dicyclomine—Rash—Triamcinolone—multiple sclerosis	0.001	0.00108	CcSEcCtD
Dicyclomine—Dermatitis—Triamcinolone—multiple sclerosis	0.001	0.00108	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—multiple sclerosis	0.001	0.00108	CcSEcCtD
Dicyclomine—Rash—Methylprednisolone—multiple sclerosis	0.001	0.00108	CcSEcCtD
Dicyclomine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000999	0.00108	CcSEcCtD
Dicyclomine—Urticaria—Prednisone—multiple sclerosis	0.000997	0.00108	CcSEcCtD
Dicyclomine—Headache—Triamcinolone—multiple sclerosis	0.000995	0.00107	CcSEcCtD
Dicyclomine—Headache—Methylprednisolone—multiple sclerosis	0.000993	0.00107	CcSEcCtD
Dicyclomine—Abdominal pain—Prednisone—multiple sclerosis	0.000993	0.00107	CcSEcCtD
Dicyclomine—Dizziness—Betamethasone—multiple sclerosis	0.000953	0.00103	CcSEcCtD
Dicyclomine—Dizziness—Dexamethasone—multiple sclerosis	0.000953	0.00103	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—multiple sclerosis	0.000949	0.00102	CcSEcCtD
Dicyclomine—Nausea—Triamcinolone—multiple sclerosis	0.000944	0.00102	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—multiple sclerosis	0.000942	0.00102	CcSEcCtD
Dicyclomine—Nausea—Methylprednisolone—multiple sclerosis	0.000942	0.00102	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—multiple sclerosis	0.000935	0.00101	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—multiple sclerosis	0.000933	0.00101	CcSEcCtD
Dicyclomine—Hypersensitivity—Prednisone—multiple sclerosis	0.000925	0.000998	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—multiple sclerosis	0.000924	0.000997	CcSEcCtD
Dicyclomine—Vomiting—Dexamethasone—multiple sclerosis	0.000917	0.000989	CcSEcCtD
Dicyclomine—Vomiting—Betamethasone—multiple sclerosis	0.000917	0.000989	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—multiple sclerosis	0.000912	0.000985	CcSEcCtD
Dicyclomine—Rash—Dexamethasone—multiple sclerosis	0.000909	0.000981	CcSEcCtD
Dicyclomine—Rash—Betamethasone—multiple sclerosis	0.000909	0.000981	CcSEcCtD
Dicyclomine—Dermatitis—Dexamethasone—multiple sclerosis	0.000908	0.00098	CcSEcCtD
Dicyclomine—Dermatitis—Betamethasone—multiple sclerosis	0.000908	0.00098	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000906	0.000978	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—multiple sclerosis	0.000905	0.000977	CcSEcCtD
Dicyclomine—Headache—Dexamethasone—multiple sclerosis	0.000903	0.000975	CcSEcCtD
Dicyclomine—Headache—Betamethasone—multiple sclerosis	0.000903	0.000975	CcSEcCtD
Dicyclomine—Asthenia—Prednisone—multiple sclerosis	0.000901	0.000972	CcSEcCtD
Dicyclomine—Pain—Methotrexate—multiple sclerosis	0.000897	0.000969	CcSEcCtD
Dicyclomine—Pruritus—Prednisone—multiple sclerosis	0.000888	0.000959	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000865	0.000933	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000858	0.000926	CcSEcCtD
Dicyclomine—Nausea—Dexamethasone—multiple sclerosis	0.000856	0.000924	CcSEcCtD
Dicyclomine—Nausea—Betamethasone—multiple sclerosis	0.000856	0.000924	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—multiple sclerosis	0.000834	0.0009	CcSEcCtD
Dicyclomine—Dizziness—Prednisone—multiple sclerosis	0.00083	0.000896	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—multiple sclerosis	0.000829	0.000895	CcSEcCtD
Dicyclomine—Vomiting—Prednisone—multiple sclerosis	0.000798	0.000862	CcSEcCtD
Dicyclomine—Rash—Prednisone—multiple sclerosis	0.000792	0.000855	CcSEcCtD
Dicyclomine—Dermatitis—Prednisone—multiple sclerosis	0.000791	0.000854	CcSEcCtD
Dicyclomine—Headache—Prednisone—multiple sclerosis	0.000787	0.000849	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000773	0.000834	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—multiple sclerosis	0.000753	0.000813	CcSEcCtD
Dicyclomine—Nausea—Prednisone—multiple sclerosis	0.000746	0.000805	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—multiple sclerosis	0.000742	0.000801	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—multiple sclerosis	0.000694	0.000749	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—multiple sclerosis	0.000667	0.00072	CcSEcCtD
Dicyclomine—Rash—Methotrexate—multiple sclerosis	0.000662	0.000714	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—multiple sclerosis	0.000661	0.000713	CcSEcCtD
Dicyclomine—Headache—Methotrexate—multiple sclerosis	0.000657	0.00071	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—multiple sclerosis	0.000623	0.000673	CcSEcCtD
Dicyclomine—CHRM2—GPCR ligand binding—CNR1—multiple sclerosis	0.000149	0.00202	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—RGS1—multiple sclerosis	0.000148	0.00201	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000143	0.00195	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000143	0.00195	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CCR1—multiple sclerosis	0.000143	0.00194	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000143	0.00194	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—GPR65—multiple sclerosis	0.000142	0.00193	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—GPR65—multiple sclerosis	0.000142	0.00193	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CCR1—multiple sclerosis	0.000141	0.00192	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000141	0.00192	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—GPR65—multiple sclerosis	0.00014	0.00191	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000138	0.00188	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000138	0.00188	CbGpPWpGaD
Dicyclomine—CYP1A1—Biological oxidations—POMC—multiple sclerosis	0.000138	0.00188	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000138	0.00187	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—LINGO1—multiple sclerosis	0.000138	0.00187	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—LINGO1—multiple sclerosis	0.000137	0.00186	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000136	0.00185	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—LINGO1—multiple sclerosis	0.000136	0.00184	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000136	0.00184	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—CXCL10—multiple sclerosis	0.000135	0.00184	CbGpPWpGaD
Dicyclomine—CHRM2—G alpha (i) signalling events—POMC—multiple sclerosis	0.000134	0.00182	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—CXCL10—multiple sclerosis	0.000134	0.00182	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CYP27B1—multiple sclerosis	0.000132	0.0018	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CYP24A1—multiple sclerosis	0.000132	0.0018	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL13—multiple sclerosis	0.00013	0.00177	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CCR1—multiple sclerosis	0.00013	0.00177	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL13—multiple sclerosis	0.00013	0.00176	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CCR1—multiple sclerosis	0.00013	0.00176	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.00013	0.00176	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	0.000129	0.00176	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CCR1—multiple sclerosis	0.000128	0.00174	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL13—multiple sclerosis	0.000128	0.00174	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GPC5—multiple sclerosis	0.000121	0.00164	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TAGAP—multiple sclerosis	0.000119	0.00162	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TAGAP—multiple sclerosis	0.000119	0.00162	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TAGAP—multiple sclerosis	0.000118	0.0016	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—CCL5—multiple sclerosis	0.000117	0.00159	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—CCL5—multiple sclerosis	0.000116	0.00158	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—CCL5—multiple sclerosis	0.000115	0.00157	CbGpPWpGaD
Dicyclomine—CHRM1—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	0.000111	0.0015	CbGpPWpGaD
Dicyclomine—CHRM3—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	0.00011	0.0015	CbGpPWpGaD
Dicyclomine—CHRM2—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	0.000109	0.00148	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000108	0.00147	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000108	0.00146	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000107	0.00145	CbGpPWpGaD
Dicyclomine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000106	0.00144	CbGpPWpGaD
Dicyclomine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000105	0.00143	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—CCR5—multiple sclerosis	0.000105	0.00143	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	0.000105	0.00143	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	0.000105	0.00143	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—CCR5—multiple sclerosis	0.000105	0.00143	CbGpPWpGaD
Dicyclomine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000104	0.00142	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—S1PR1—multiple sclerosis	0.000104	0.00142	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—CCR5—multiple sclerosis	0.000104	0.00141	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—S1PR1—multiple sclerosis	0.000104	0.00141	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—S1PR1—multiple sclerosis	0.000103	0.0014	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000103	0.00139	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GPC5—multiple sclerosis	0.000101	0.00138	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GPC5—multiple sclerosis	0.000101	0.00137	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.0001	0.00136	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—RRM1—multiple sclerosis	0.0001	0.00136	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GPC5—multiple sclerosis	0.0001	0.00136	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	9.82e-05	0.00134	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PTGER4—multiple sclerosis	9.79e-05	0.00133	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PTGER4—multiple sclerosis	9.7e-05	0.00132	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GPC5—multiple sclerosis	9.6e-05	0.0013	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	9.49e-05	0.00129	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCR3—multiple sclerosis	9.46e-05	0.00129	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCR3—multiple sclerosis	9.37e-05	0.00127	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CCL3—multiple sclerosis	9.27e-05	0.00126	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CCL3—multiple sclerosis	9.24e-05	0.00126	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CCR2—multiple sclerosis	9.23e-05	0.00125	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CCR2—multiple sclerosis	9.2e-05	0.00125	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CCL3—multiple sclerosis	9.15e-05	0.00124	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CCR2—multiple sclerosis	9.11e-05	0.00124	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PTGER4—multiple sclerosis	8.92e-05	0.00121	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PTGER4—multiple sclerosis	8.89e-05	0.00121	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—RGS1—multiple sclerosis	8.86e-05	0.0012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—RGS1—multiple sclerosis	8.83e-05	0.0012	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PTGER4—multiple sclerosis	8.81e-05	0.0012	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—RGS1—multiple sclerosis	8.75e-05	0.00119	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCR3—multiple sclerosis	8.62e-05	0.00117	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCR3—multiple sclerosis	8.59e-05	0.00117	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CNR1—multiple sclerosis	8.52e-05	0.00116	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCR3—multiple sclerosis	8.51e-05	0.00116	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CNR1—multiple sclerosis	8.49e-05	0.00115	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CNR1—multiple sclerosis	8.41e-05	0.00114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GPR65—multiple sclerosis	8.4e-05	0.00114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CCR2—multiple sclerosis	8.38e-05	0.00114	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GPR65—multiple sclerosis	8.37e-05	0.00114	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CCR2—multiple sclerosis	8.35e-05	0.00114	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GPR65—multiple sclerosis	8.29e-05	0.00113	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CCR2—multiple sclerosis	8.27e-05	0.00112	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	8.25e-05	0.00112	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—POMC—multiple sclerosis	8.23e-05	0.00112	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	8.22e-05	0.00112	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—POMC—multiple sclerosis	8.2e-05	0.00111	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—POMC—multiple sclerosis	8.12e-05	0.0011	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—IL6—multiple sclerosis	8.09e-05	0.0011	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR ligand binding—CCL2—multiple sclerosis	8.05e-05	0.00109	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR ligand binding—CCL2—multiple sclerosis	8.02e-05	0.00109	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—RRM1—multiple sclerosis	7.96e-05	0.00108	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR ligand binding—CCL2—multiple sclerosis	7.94e-05	0.00108	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CNR1—multiple sclerosis	7.73e-05	0.00105	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CNR1—multiple sclerosis	7.71e-05	0.00105	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL13—multiple sclerosis	7.68e-05	0.00104	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCR1—multiple sclerosis	7.68e-05	0.00104	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	7.67e-05	0.00104	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL13—multiple sclerosis	7.66e-05	0.00104	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCR1—multiple sclerosis	7.66e-05	0.00104	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCL10—multiple sclerosis	7.64e-05	0.00104	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CNR1—multiple sclerosis	7.64e-05	0.00104	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL13—multiple sclerosis	7.58e-05	0.00103	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCR1—multiple sclerosis	7.58e-05	0.00103	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCL10—multiple sclerosis	7.57e-05	0.00103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL10—multiple sclerosis	6.96e-05	0.000947	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL10—multiple sclerosis	6.94e-05	0.000943	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL10—multiple sclerosis	6.87e-05	0.000934	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—IL6—multiple sclerosis	6.69e-05	0.000909	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CCL5—multiple sclerosis	6.6e-05	0.000897	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CCL5—multiple sclerosis	6.58e-05	0.000894	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CCL5—multiple sclerosis	6.52e-05	0.000886	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	6.34e-05	0.000861	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	6.32e-05	0.000859	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.17e-05	0.000839	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CCL5—multiple sclerosis	5.99e-05	0.000815	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CCL5—multiple sclerosis	5.98e-05	0.000812	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CCR5—multiple sclerosis	5.95e-05	0.000808	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CCR5—multiple sclerosis	5.93e-05	0.000806	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CCL5—multiple sclerosis	5.92e-05	0.000804	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CCR5—multiple sclerosis	5.87e-05	0.000798	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	5.86e-05	0.000797	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—IL2RA—multiple sclerosis	5.84e-05	0.000794	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—IL2RA—multiple sclerosis	5.79e-05	0.000786	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—BCHE—multiple sclerosis	5.75e-05	0.000782	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCL3—multiple sclerosis	5.47e-05	0.000744	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCL3—multiple sclerosis	5.46e-05	0.000742	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCL3—multiple sclerosis	5.4e-05	0.000734	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CCR5—multiple sclerosis	5.4e-05	0.000734	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CCR5—multiple sclerosis	5.38e-05	0.000732	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CCR5—multiple sclerosis	5.33e-05	0.000725	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL2RA—multiple sclerosis	5.32e-05	0.000723	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL2RA—multiple sclerosis	5.31e-05	0.000721	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.3e-05	0.000721	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTGER4—multiple sclerosis	5.27e-05	0.000716	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL2RA—multiple sclerosis	5.25e-05	0.000714	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTGER4—multiple sclerosis	5.25e-05	0.000714	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTGER4—multiple sclerosis	5.2e-05	0.000707	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PGR—multiple sclerosis	5.19e-05	0.000705	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PGR—multiple sclerosis	5.17e-05	0.000703	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PGR—multiple sclerosis	5.12e-05	0.000696	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCR3—multiple sclerosis	5.09e-05	0.000692	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCR3—multiple sclerosis	5.07e-05	0.00069	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CD28—multiple sclerosis	5.04e-05	0.000685	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CD28—multiple sclerosis	5.03e-05	0.000683	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCR3—multiple sclerosis	5.02e-05	0.000683	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CD28—multiple sclerosis	4.98e-05	0.000676	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCR2—multiple sclerosis	4.95e-05	0.000673	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCR2—multiple sclerosis	4.94e-05	0.000671	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCR2—multiple sclerosis	4.89e-05	0.000664	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.83e-05	0.000657	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—POMC—multiple sclerosis	4.65e-05	0.000632	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—POMC—multiple sclerosis	4.63e-05	0.00063	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—POMC—multiple sclerosis	4.59e-05	0.000624	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—BCHE—multiple sclerosis	4.57e-05	0.000621	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CNR1—multiple sclerosis	4.57e-05	0.000621	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CNR1—multiple sclerosis	4.55e-05	0.000619	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CNR1—multiple sclerosis	4.51e-05	0.000613	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—POMC—multiple sclerosis	4.22e-05	0.000574	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—POMC—multiple sclerosis	4.21e-05	0.000572	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—POMC—multiple sclerosis	4.17e-05	0.000566	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CCL2—multiple sclerosis	4.13e-05	0.000561	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CCL2—multiple sclerosis	4.12e-05	0.00056	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL10—multiple sclerosis	4.11e-05	0.000559	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL10—multiple sclerosis	4.1e-05	0.000557	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CCL2—multiple sclerosis	4.08e-05	0.000554	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL10—multiple sclerosis	4.06e-05	0.000552	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—TYK2—multiple sclerosis	3.75e-05	0.00051	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—TYK2—multiple sclerosis	3.74e-05	0.000508	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—TYK2—multiple sclerosis	3.7e-05	0.000503	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CD86—multiple sclerosis	3.6e-05	0.000489	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CD86—multiple sclerosis	3.59e-05	0.000487	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CD86—multiple sclerosis	3.55e-05	0.000483	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCL5—multiple sclerosis	3.54e-05	0.000481	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCL5—multiple sclerosis	3.53e-05	0.00048	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCL5—multiple sclerosis	3.5e-05	0.000475	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—APOE—multiple sclerosis	3.46e-05	0.00047	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—IL2—multiple sclerosis	3.44e-05	0.000467	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—IL2—multiple sclerosis	3.43e-05	0.000466	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—IL2—multiple sclerosis	3.39e-05	0.000461	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SPP1—multiple sclerosis	3.28e-05	0.000446	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SPP1—multiple sclerosis	3.27e-05	0.000444	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SPP1—multiple sclerosis	3.24e-05	0.00044	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCR5—multiple sclerosis	3.19e-05	0.000434	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCR5—multiple sclerosis	3.18e-05	0.000432	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCR5—multiple sclerosis	3.15e-05	0.000428	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2RA—multiple sclerosis	3.14e-05	0.000427	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2RA—multiple sclerosis	3.13e-05	0.000426	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL2—multiple sclerosis	3.12e-05	0.000424	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL2—multiple sclerosis	3.11e-05	0.000423	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2RA—multiple sclerosis	3.1e-05	0.000422	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL2—multiple sclerosis	3.08e-05	0.000419	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—POMC—multiple sclerosis	2.97e-05	0.000404	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—APOE—multiple sclerosis	2.9e-05	0.000394	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—APOE—multiple sclerosis	2.89e-05	0.000393	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—APOE—multiple sclerosis	2.87e-05	0.000389	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—APOE—multiple sclerosis	2.75e-05	0.000374	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALB—multiple sclerosis	2.71e-05	0.000368	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CD80—multiple sclerosis	2.62e-05	0.000357	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CD80—multiple sclerosis	2.62e-05	0.000356	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CD80—multiple sclerosis	2.59e-05	0.000352	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—POMC—multiple sclerosis	2.49e-05	0.000339	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—POMC—multiple sclerosis	2.49e-05	0.000338	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—POMC—multiple sclerosis	2.46e-05	0.000335	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCL2—multiple sclerosis	2.44e-05	0.000332	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCL2—multiple sclerosis	2.43e-05	0.000331	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCL2—multiple sclerosis	2.41e-05	0.000327	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAPK1—multiple sclerosis	2.39e-05	0.000324	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAPK1—multiple sclerosis	2.38e-05	0.000323	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—POMC—multiple sclerosis	2.36e-05	0.000321	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAPK1—multiple sclerosis	2.36e-05	0.00032	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TYK2—multiple sclerosis	2.22e-05	0.000301	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TYK2—multiple sclerosis	2.21e-05	0.0003	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TYK2—multiple sclerosis	2.19e-05	0.000297	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALB—multiple sclerosis	2.15e-05	0.000293	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2—multiple sclerosis	1.84e-05	0.000251	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2—multiple sclerosis	1.84e-05	0.00025	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL6—multiple sclerosis	1.83e-05	0.000249	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL6—multiple sclerosis	1.83e-05	0.000248	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2—multiple sclerosis	1.82e-05	0.000247	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL6—multiple sclerosis	1.81e-05	0.000246	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MMP9—multiple sclerosis	1.74e-05	0.000237	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MMP9—multiple sclerosis	1.74e-05	0.000236	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MMP9—multiple sclerosis	1.72e-05	0.000234	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STAT3—multiple sclerosis	1.55e-05	0.000211	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STAT3—multiple sclerosis	1.55e-05	0.00021	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STAT3—multiple sclerosis	1.53e-05	0.000208	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—multiple sclerosis	1.44e-05	0.000196	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TGFB1—multiple sclerosis	1.44e-05	0.000195	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—multiple sclerosis	1.44e-05	0.000195	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TGFB1—multiple sclerosis	1.43e-05	0.000195	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—multiple sclerosis	1.42e-05	0.000193	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TGFB1—multiple sclerosis	1.42e-05	0.000193	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK1—multiple sclerosis	1.41e-05	0.000192	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK1—multiple sclerosis	1.41e-05	0.000191	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK1—multiple sclerosis	1.39e-05	0.000189	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6—multiple sclerosis	1.08e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6—multiple sclerosis	1.08e-05	0.000147	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6—multiple sclerosis	1.07e-05	0.000145	CbGpPWpGaD
